PHARMASYNTHESE
NACE 21.10 in FR. Public registry data, filed financials, business card, and annual valuation trend on one indexed company profile.
FRFiled 2025Updated Jul 12, 2026
PHARMASYNTHESE
NACE 21.10
Frankrijk
Your value, under scrutiny
What could a buyer discount here?
This is a first signal from public filings, not a sale price. It surfaces where a business may be exposed before a lender, buyer or successor turns uncertainty into a discount. Add current figures privately to see what to strengthen first.
Context: Stable SMEMethod: Public accounts multiple
Latest estimate
First value signal
Create a free account to see what could be costing this business valueThe worst time to discover a weak spot is when someone else prices it.
A lower price rarely starts at the negotiation table. It starts with risks left unaddressed. Sign in to see what may weaken this business before financing, succession or a sale makes the question urgent.
See what could be weakening this businessFree · private by default
Value pathSame pace: market decides.
Growth goalsPublic preview
This is a starting point, not a sale price. Owner context reveals the risks that can become a discount—and the moves that make the business stronger.
Public figures